Comparison of the kinetics of methylene-diphosphonate (MDP) and dicarboxypropan-diphosphonic acid (DPD), two radio-diagnostics for bone scintigraphy

Schroth, H.-J.; Hausinger, Franz; Garth, H.; Oberhausen, E.

doi:10.1007/bf00256849

Cited by 8 publications

(6 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, higher urinary excretion results in lower skeletal uptake. In humans, it was reported that the urinary excretion of MDP was 25% higher than that of DPD 21 . In an experimental study on dogs, MDP had a higher urinary excretion rate than HDP (76.5% and 59%, respectively) 18 .…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

The impact of different bone tracers and acquisition times on image quality of equine bone scintigraphy

Mageed

Dyab²,

Swagemakers

et al. 2022

Vet Radiology Ultrasound

View full text Add to dashboard Cite

The impact of different acquisition times (AqT) and technetium‐99 m–labeled (99mTc) diphosphonates on the image quality of bone scintigraphy is poorly documented in horses. The aim of this prospective experimental study was to evaluate the impact of varying 99mTc‐disphosphonates and AqT on semiquantitative and qualitative image parameters of bone scintigraphy in horses. Twenty‐four horses undergoing bone scintigraphy were divided equally and randomly into methylene‐ (MDP), hydroxymethylene‐ (HDP), and dicarboxypropane diphosphonate (DPD) groups. Lateral scintigraphic images of the antebrachium were obtained 3 h post 99mTC‐diphosphonate injection using three AqT (60, 90, 120 s). The images were analyzed semiquantitatively using the bone‐soft tissue ratio (B:ST), signal‐to‐noise ratio (SNR), contrast‐to‐noise ratio (CNR), and image contrast. Furthermore, a blinded qualitative analysis was performed using a visual grading analysis. The results showed that DPD images had a significantly higher B:ST ratio than MDP images (P < .01) but not HDP images in all AqT (P > .08). However, DPD and HPD images acquired at 60 s had significantly higher CNR (P < .05) than those acquired at 90 and 120 s. The qualitative analysis revealed no significant differences between 99mTc‐diphosphonates at AqT 60 and 90 s. However, MDP images acquired at 120 s had significantly lower image quality compared to DPD and HDP (P = .01 and .03, respectively). In conclusion, the bone tracers affected the semiquantitative image parameters but not the qualitative analysis findings. Increasing AqT did not necessarily improve the image quality. Therefore, decreasing the AqT enabled a reduction in personnel radiation exposure.

show abstract

Section: Discussionmentioning

confidence: 92%

“…In humans, it was reported that the urinary excretion of MDP was 25% higher than that of DPD. 21 In an experimental study on dogs, MDP had a higher urinary excretion rate than HDP (76.5% and 59%, respectively). 18 Based on our review of the literature, the pharmacology of 99m Tc-diphosphonates has been poorly documented in horses.…”

Section: Discussionmentioning

confidence: 96%

The impact of different bone tracers and acquisition times on image quality of equine bone scintigraphy

Mageed

Dyab²,

Swagemakers

et al. 2022

Vet Radiology Ultrasound

View full text Add to dashboard Cite

show abstract

“…Moreover, our study was performed on most likely sound equine limbs; therefore, HDP and MDP could not be compared regarding their lesion detection ability. Some authors reported greater retention of HDP and DPD within the skeleton; however, there was no difference between these substances and MDP in detecting bone lesions 9,29 …”

Section: Discussionmentioning

confidence: 97%

Equine skeletal scintigraphy: Comparing normal bone‐to‐soft tissue ratio 2 and 4 hours after injection with either hydroxymethylene diphosphonate or methylene diphosphonate

et al. 2022

View full text Add to dashboard Cite

Background: In equine skeletal scintigraphy, there is no information about the possible influence of different phosphonate compounds on image quality. Methods: This prospective randomised study determined bone uptake changes and image quality for hydroxymethylene diphosphonate (HDP) and methylene diphosphonate (MDP) in equine patients at different time points. Scintigraphic images of the radius and the tibia of 20 horses were acquired at 2 and 4 hours after injection of either technetium-labelled HDP or MDP. Three regions of interest were identified-in the bone diaphysis, adjacent soft tissue and background area-to determine the normal bone-to-soft tissue ratio (BSR). Qualitative analysis was performed using a modified scoring system. Results: In terms of BSR and count rates, HDP showed a slightly better incorporation into bone compared to MDP, but significant differences were only detected for count rates at 4 hours after injection (p = 0.048). The radiopharmaceutical used did not influence qualitative image scoring, which was correlated with the BSR (ρ = 0.49; p ≤ 0.001). Conclusion:The choice of HDP or MDP for equine skeletal scintigraphy does not seem to substantially affect BSR and qualitative image scoring. Further studies with a larger sample size, including the evaluation of lesion detection ability for both bone-seeking agents, are needed.

show abstract

“…DPD was developed at Haechst, Germany (Schwarz and Kloss 1981;Schwarz et al 1991), and compared favorably with MDP (Buell et al 1982;Godart et al 1986;Hale et al 1981;Pauwels et al 1983;Schroth et al 1984). DPD is another efficient phosphonate complex that has been widely used as Teceos.…”

Section: Pretreatment Of Red Blood Cells (Rbc) With Mdp For In Vivo Lmentioning

confidence: 99%

Technetium-99m Pharmaceuticals

Zolle¹

2007

105

View full text Add to dashboard Cite

Foreword 99m Tc pharmaceuticals mark the beginning of diagnostic nuclear medicine and have contributed to patient care worldwide. Since the short-lived radionuclide was introduced for thyroid imaging in 1964, it has attracted much attention and stimulated clinical research. Little was known about element 43, except that it was an artificial radionuclide obtained by the radioactive decay of molybdenum-99. No wonder specialists from all fields joined medical institutions in the United States to participate in the exploration of its chemistry.This textbook gives an account of the accomplishments related to the development of 99m Tc pharmaceuticals and their application in diagnostic nuclear medicine. Since radioactive drug development is a multidisciplinary task, experts working in nuclear medicine and research institutions have contributed valuable information concerning the preparation with sterile kits, methods of quality control, and the use of 99m Tc pharmaceuticals in patients. In addition, the legal aspects governing production and clinical application are also considered.99m Tc pharmaceuticals in nuclear medicine are presented in two parts. Part 1 includes basic principles and methods used for preparation and analysis, in particular the chemistry of technetium-99m and methods described for the synthesis of complexes and conjugates of technetium-99m, the characteristics and performance of the 99 Mo/ 99m Tc generator system, the importance of kits and formulations for one-step labeling, and safety aspects for labeling blood cells. Special emphasis is given to analytical methods verifying pharmaceutical quality. The quality standards of good manufacturing practice (GMP) for 99m Tc pharmaceuticals and purity standards of the pharmacopeia (European Pharmacopeia and United States Pharmacopeia) have been considered as part of the concept of quality assurance.Part 2 presents 26 monographs of 99m Tc pharmaceuticals, concerning the preparation and safe clinical application. Each monograph provides information on the characteristics of the radiotracer based on chemistry, factors affecting the preparation and in vivo stability, pharmacokinetics and elimination properties, as well as details concerning the clinical application. For each clinical procedure, the effective radiation dose of the patient has been calculated. Methods recommended for quality control and actual results are included.Each radiopharmaceutical is listed under the name used in daily practice. The chemical name, the abbreviated name, and the officinal name in the pharmacopeia are also stated. Listing the trade names may facilitate understanding, especially when relating to products in the literature, which over the years have changed manufacturers.The presentation of 99m Tc pharmaceuticals as monographs serves a practical purpose: it offers relevant information on kit preparation and clinical application at a glance. These monographs provide a wide spectrum of information on 99m Tc pharmaceuticals for daily practice in nuclear medicine, serving as a r...

show abstract

Comparison of the kinetics of methylene-diphosphonate (MDP) and dicarboxypropan-diphosphonic acid (DPD), two radio-diagnostics for bone scintigraphy

Cited by 8 publications

References 2 publications

The impact of different bone tracers and acquisition times on image quality of equine bone scintigraphy

The impact of different bone tracers and acquisition times on image quality of equine bone scintigraphy

Equine skeletal scintigraphy: Comparing normal bone‐to‐soft tissue ratio 2 and 4 hours after injection with either hydroxymethylene diphosphonate or methylene diphosphonate

Technetium-99m Pharmaceuticals

Contact Info

Product

Resources

About